152 related articles for article (PubMed ID: 33750129)
21. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.
Thougaard AV; Langer SW; Hainau B; Grauslund M; Juhl BR; Jensen PB; Sehested M
Toxicology; 2010 Feb; 269(1):67-72. PubMed ID: 20079798
[TBL] [Abstract][Full Text] [Related]
22. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase II poisoning by ICRF-193.
Huang KC; Gao H; Yamasaki EF; Grabowski DR; Liu S; Shen LL; Chan KK; Ganapathi R; Snapka RM
J Biol Chem; 2001 Nov; 276(48):44488-94. PubMed ID: 11577077
[TBL] [Abstract][Full Text] [Related]
25. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
26. The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II.
Hasinoff BB; Takeda K; Ferrans VJ; Yu ZX
Anticancer Drugs; 2002 Mar; 13(3):255-8. PubMed ID: 11984069
[TBL] [Abstract][Full Text] [Related]
27. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
28. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
Hasinoff BB; Hellmann K; Herman EH; Ferrans VJ
Curr Med Chem; 1998 Feb; 5(1):1-28. PubMed ID: 9481032
[TBL] [Abstract][Full Text] [Related]
29. Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs.
Yadav AA; Chee GL; Wu X; Patel D; Yalowich JC; Hasinoff BB
Bioorg Med Chem; 2015 Jul; 23(13):3542-51. PubMed ID: 25922181
[TBL] [Abstract][Full Text] [Related]
30. Interaction of the DNA topoisomerase II catalytic inhibitor meso-2,3-bis(3,5-dioxopiperazine-1-yl)butane (ICRF-193), a bisdioxopiperazine derivative, with the conserved region(s) of eukaryotic but not prokaryotic enzyme.
Sato M; Ishida R; Narita T; Kato J; Ikeda H; Fukazawa H; Andoh T
Biochem Pharmacol; 1997 Sep; 54(5):545-50. PubMed ID: 9337070
[TBL] [Abstract][Full Text] [Related]
31. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
32. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
[TBL] [Abstract][Full Text] [Related]
33. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.
Simůnek T; Sterba M; Popelová O; Kaiserová H; Adamcová M; Hroch M; Hasková P; Ponka P; Gersl V
Br J Pharmacol; 2008 Sep; 155(1):138-48. PubMed ID: 18536744
[TBL] [Abstract][Full Text] [Related]
34. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
Kik K; Szmigiero L
Postepy Hig Med Dosw (Online); 2006; 60():584-90. PubMed ID: 17115008
[TBL] [Abstract][Full Text] [Related]
35. The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy.
Szponar J; Ciechanski E; Ostrowska-Lesko M; Gorska A; Tchorz M; Dabrowska A; Dudka J; Murias M; Kowalczyk M; Korga-Plewko A; Mandziuk S
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373350
[TBL] [Abstract][Full Text] [Related]
36. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
37. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
[TBL] [Abstract][Full Text] [Related]
38. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
[TBL] [Abstract][Full Text] [Related]
39. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Hasinoff BB; Schroeder PE; Patel D
Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
Hasinoff BB; Wu X; Yang Y
J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
